GBS/CIDP Foundation Company Profile

10:45 EDT 19th March 2018 | BioPortfolio

GBS is an inflammatory disorder of the peripheral nerves and is characterized by the rapid onset of weakness and often paralysis of the legs, arms, breathing muscles and face. GBS can develop in persons of any age. CIDP is a rare disorder of the peripheral nerves with weakness occurring over two or more months and is characterized by gradually increasing weakness of the legs and, to a lesser extent, the arms. It is caused by damage to the covering of the nerves called myelin.

News Articles [421 Associated News Articles listed on BioPortfolio]

Medical News Today: What to know about CIDP

A look at chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where that causes nerve damage. Included is detail on treatment.

GeNeuro Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

GNbAC1 targets pHERV-W env, which is found in half of CIDP patients Forthcoming discussions expected with the FDA for the design of a proof-of-concept Phase 2 clinical study Regulatory News: GeNeu...

[Articles] Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

This study, which is to our knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were effica...

CSL's Hizentra gains approvals for rare disease CIDP

SCIg: An Option as Maintenance Tx for CIDP (CME/CE)

(MedPage Today) -- Relapses or withdrawals in 33% of patients in PATH trial

The Ewing Marion Kauffman Foundation: Entrepreneurship and Success

In this interview, Lesa Mitchell, VP Kauffman Foundation, Ewing Marion Kauffman Foundation, talks to Dr Fintan Walton about: • the Foundation’s origins and its focus on entrepreneurship • its re...

US nod for CSL Behring’s Hizentra

US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that c...

ASN Foundation for Kidney Research Grants open today - October 11

The ASN Foundation for Kidney Research (ASN Foundation) has now opened applications for its Career Development Grants, Clinician Educator Grant, and Research Fellowship program. The ASN Foundation fun...

Drugs and Medications [451 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [227 Associated PubMed Articles listed on BioPortfolio]

CIDP and other inflammatory neuropathies in diabetes - diagnosis and management.

Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most...

Electrodiagnostic errors contribute to CIDP misdiagnosis.

Documentation of peripheral nerve demyelination is an important part of the CIDP diagnostic process.

Chronic inflammatory demyelinating polyneuropathy.

As a syndrome with typical and atypical cases, chronic inflammatory demyelinating polyneuropathy (CIDP) has been a difficult disorder to diagnose and treat. The pathophysiologic basis for CIDP has not...

Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review.

A systematic review of the literature was performed on the association of chronic inflammatory demyelinating polyneuropathy (CIDP) with malignancy. Hematologic disorders are the most common associatio...

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

CIDP patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2 g/kg body weight. Only a minority of patients have a sustained improvement, and most require ongo...

Clinical Trials [241 Associated Clinical Trials listed on BioPortfolio]

Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of treatme...

Panzyga in CIDP Administered at Different Infusion Rates

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune glob...

Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)

The main purpose of this study is to assess the clinical feasibility of diffusion tensor imaging (DTI) for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

The purpose of this study is to assess the long-term safety, tolerability, and immunogenicity of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous (IGSC) facilitated with r...

Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an acquired neuropathy characterized by an inflammatory multifocal segmental demyelination. Due to the clinical heteroge...

Companies [1340 Associated Companies listed on BioPortfolio]

The GBS/CIDP Foundation International

GBS/CIDP Foundation

GBS is an inflammatory disorder of the peripheral nerves and is characterized by the rapid onset of weakness and often paralysis of the legs, arms, breathing muscles and face. GBS can develop in pers...

AVA Foundation

The AVA Foundation is a 501(c)(3) educational and research foundation dedicated to saving lives through promoting risk-free vascular access and evidence-based clinical practice. T...

COSHAR Foundation

The COSHAR Foundation is a 501( c )3 organization dedicated to "Impacting the Health of the World, One Community at a Time." The COSHAR Foundation's NHMN includes more than 14,000 churches and 220 co...

The NASCAR Foundation

The National Association for Stock Car Auto Racing, Inc., (NASCAR) launched The NASCAR Foundation in January 2006. The Foundation is a 501(c)(3) non-profit entity that embodies the compassion of the N...

More Information about "GBS/CIDP Foundation" on BioPortfolio

We have published hundreds of GBS/CIDP Foundation news stories on BioPortfolio along with dozens of GBS/CIDP Foundation Clinical Trials and PubMed Articles about GBS/CIDP Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GBS/CIDP Foundation Companies in our database. You can also find out about relevant GBS/CIDP Foundation Drugs and Medications on this site too.

Quick Search


Relevant Topic

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Corporate Database Quicklinks

Searches Linking to this Company Record